Literature DB >> 18393812

Nasal immunization studies by cationic, fusogenic and cationic-fusogenic liposomes encapsulated with tetanus toxoid.

M Tafaghodi1, M R Jaafari, S A Sajadi Tabassi.   

Abstract

Particulate antigens are more effective than soluble antigens in induction of systemic and mucosal immunity; possibly because they are more efficiently endocytosed by mucosal-associated lymphoid tissue (MALT) M cells. In this study, we determined the systemic and mucosal immune responses in rabbits following intranasal immunization with tetanus toxoid (TT) entrapped in cationic, fusogenic and cationic-fusogenic liposomes. Liposomes containing TT were prepared by dehydration-rehydration method. The volume mean diameter of cationic, fusogenic and cationic-fusogenic liposomes were 3.4 +/- 0.6, 4.3 +/- 2.3 and 3.4 +/- 1.5 microm, respectively. Encapsulation efficiency of TT in cationic, fusogenic and cationic-fusogenic liposomes was respectively determined as 49.1 +/- 8.4%, 48.5 +/- 2.1% and 50.8 +/- 4.9%. After 3 months, the leaking of encapsulated TT from liposomes ranged between 2.02 - 5.46%. Immunoreactivities of encapsulated TT in all kinds of liposomes were completely preserved, as studied by Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Enzyme-Linked Immunosorbent Assay (ELISA). The highest serum immunoglobulin G (IgG) and antitoxin titers were observed in groups immunized with solution formulation (P< 0.001). However, the highest mucosal secretory IgA (sIgA) titers were achieved by fusogenic liposomes (five times more titers compared with TT solution, and 15 times more titers compared with i.m. vaccine), followed by cationic-fusogenic liposomes. No hemolysis was occurred on incubation of liposomes and human erythrocytes. Also after nasal administration of plain liposomes to human volunteers, no local irritation was seen. This study suggests that intranasal administration of fusogenic and cationic-fusogenic liposomes encapsulated with vaccines could be an effective way for inducing mucosal immune responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18393812     DOI: 10.2174/156720108783954833

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  6 in total

Review 1.  Nanomedicine in GI.

Authors:  Hamed Laroui; David S Wilson; Guillaume Dalmasso; Khalid Salaita; Niren Murthy; Shanthi V Sitaraman; Didier Merlin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-09       Impact factor: 4.052

Review 2.  Alginate as a Promising Biopolymer in Drug Delivery and Wound Healing: A Review of the State-of-the-Art.

Authors:  Mohammad A S Abourehab; Rahul R Rajendran; Anshul Singh; Sheersha Pramanik; Prachi Shrivastav; Mohammad Javed Ansari; Ravi Manne; Larissa Souza Amaral; A Deepak
Journal:  Int J Mol Sci       Date:  2022-08-12       Impact factor: 6.208

3.  Mucosal Adjuvant Potential of Quillaja saponins and Cross-linked Dextran Microspheres, Co-administered with Liposomes Encapsulated with Tetanus Toxoid.

Authors:  Faezeh Moghadam Ariaee; Mohsen Tafaghodi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

4.  Immunization Against Cutaneous Leishmaniasis by Alginate Microspheres Loaded With Autoclaved Leishmania Major (ALM) and Quillaja Saponins.

Authors:  Mohsen Tafaghodi; Maryam Eskandari; Ali Khamesipour; Mahmoud Reza Jaafari
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

5.  Preparation, characterization and in vivo evaluation of alginate-coated chitosan and trimethylchitosan nanoparticles loaded with PR8 influenza virus for nasal immunization.

Authors:  Jafar Mosafer; Amir-Hossein Sabbaghi; Ali Badiee; Solmaz Dehghan; Mohsen Tafaghodi
Journal:  Asian J Pharm Sci       Date:  2018-05-10       Impact factor: 6.598

6.  Strategies for intranasal delivery of vaccines.

Authors:  Mehfuz Zaman; Saranya Chandrudu; Istvan Toth
Journal:  Drug Deliv Transl Res       Date:  2012-07-12       Impact factor: 4.617

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.